Meet the 2021 Judges
Global Generics & Biosimilars Awards Judges
We are currently confirming the 2021 judges and so far we have:
Please scroll to the right to see more judges
Adrian van den Hoven
Douglas M Long
James Vane Tempest
Adrian van den Hoven
Adrian van den Hoven joined Medicines for Europe as a Director General in September 2013. His priorities at Medicines for Europe are to stimulate competition in off-patent medicine markets, to foster market access for generic, biosimilar and value added medicines, to support policy measures for sustainable pricing, to promote high regulatory standards while ensuring that the associated costs can be integrated into market dynamics and to develop a coherent EU industrial strategy to support the long-term viability of the generic, biosimilar and value added medicines industries. Prior to joining Medicines for Europe, Adrian van den Hoven was Deputy-Director General of BUSINESSEUROPE where he was responsible for the International Relations department, covering trade negotiations and bilateral relations, and the Industry department, covering industrial, energy, environmental and research policy. He previously worked as an International Relations researcher and an adjunct professor in Italy (EUI), France (Nice) and Canada (Windsor). He obtained his doctorate in Political Science from the University of Nice, France in 2000.
Ascher Resources with 50 years extensive global healthcare experience, including innovator R&D pharmaceuticals, OTC and generic companies, working with government departments, law firms, venture capital companies and industry associations. Alan was Principal, Thought Leadership Global Generics and Biosimilars, IMS Health; Exec VP, Europe Generics Dr Reddy’s; VP, Global Corporate Strategy PLIVA; European Marketing Director, Medeva. Earlier positions: General Manager, Rhône-Poulenc Rorer UK; Marketing Director, Revlon Healthcare; General Manager, Institute Mérieux UK; management roles with Servier, SmithKline & French and Upjohn. Alan has been an expert witness, patent litigation; a guest lecturer, University of Wales; Chairman, Technical Advisory Group, Access to Medicines Foundation; member, PMCPA Appeals Board and Fellow, International Doctors’ Association.
Aurelio creates topical and forward-looking strategic content relevant to pharma executives worldwide and publishes articles, blogs, and white papers on a regular basis.
Aurelio’s predominant focus is on off-patent markets where he generates evidence-led insights with a view to spark high-level discourse on biosimilars, generics and value added medicines. Moreover, he is involved in numerous projects exploring the interface between healthcare and digital technology. He is considered a subject matter expert in these areas and speaks at numerous conferences worldwide, presents at board-level meetings and engages in consulting projects.
Prior to IQVIA, Aurelio has worked in Discovery R&D and in various strategy consulting roles. He holds an MSci in Chemistry from Imperial College London.
By education a pharmacist with a PhD in Pharmaceutical Technology - worked for over 25 years for STADA Arzneimittel AG in very different business areas like General Management, Operations, M&A, M&S and Communications. Finally, he was appointed as STADA Executive Board Member for Production and Development from 2010 to 2013.
Since 2014 Axel is working as Consultant – mainly but not only in the Pharmaceutical Industry. After some years working as Senior Advisor of Arthur D. Little he joined 2018 Fidelio Healthcare Partners as Associated Partner. In addition, Axel is non-executive member of several supervisory and advisory boards.
Founded Wavedata in 2000 and has led it since then to be a major player in UK competitive intelligence, especially in keeping clients informed about their competitor’s pricing strategies.
Prior to this Charles was Business Information Manager at Ivax,
And before that he was in sales with Napp, Fisons and Baker Norton.
Charles holds an MBA from Birmingham University and a BSc from Sheffield University.
Douglas M. Long
Doug Long is Vice President of Industry Relations at IQVIA (formerly QuintilesIMS) one the world’s largest pharmaceutical information company. IQVIA offers services to the pharmaceutical industry in over 101 countries around the globe.
Doug has been with IQVIA since 1989. His fundamental task is to help secure data for all existing and new databases supported by IQVIA, manage supplier, manufacturer & association relationships, and develop information for data partners. As direct consequence of his involvement in these areas, Doug has considerable experience with, and a unique perspective on, the changing U.S. and global healthcare marketplace and pharmaceutical distribution.
James Vane Tempest
Maja Sercic is a Policy & Science Manager at Medicines for Europe and coordinator of Value Added medicines sector group. Maja is pharmacists by training. Before joining Medicines for Europe, she worked in the pharmaceutical industry, working on the off-patent development projects liaising with the external partners across the industry. Medicines for Europe represents the pharmaceutical companies supplying the largest share of medicines across Europe and is the voice of the generic, biosimilar and value-added industries. As a leading partner for better healthcare aims to increase the health and wellbeing of all Europeans through better access to high-quality medicines.
Suzette Kox was nominated in February 2019 as the first Secretary General of the International Generic and Biosimilar Medicines Association (IGBA). Universal access to cost-effective medicines has always been her motivation to work in the off-patent medicines sector.
Suzette has been involved with IGBA since its inception in 1997 in her capacity as Senior Director International and Coordinator of the Biosimilar Medicines Group at Medicines for Europe (formerly EGA). She was the first Chairperson of the IGBA Biosimilars Committee.
Before joining the European association in 2001, Suzette worked for 10 years in regulatory affairs and management for the German pharmaceutical company ratiopharm (now Teva) and, at the same time, acted as Chair of the EGA Regulatory & Scientific Affairs Committee.